Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma

被引:25
|
作者
Lin, Ching-Jung [1 ]
Hsu, Teh-Fu [1 ,2 ,3 ]
Chang, Yen-Hou [1 ,3 ]
Huang, Ben-Shian [1 ,3 ,4 ]
Jiang, Ling-Yu [1 ,3 ]
Wang, Peng-Hui [1 ,3 ,4 ]
Chen, Yi-Jen [1 ,3 ,4 ,5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Emergency Med, Taipei, Taiwan
[3] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[4] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
来源
关键词
Adenomyosis; Adenomyoma; Conservative uterine-sparing surgery; Gonadotropin releasing hormone agonist; Levonorgestrel-releasing intrauterine system; MEDICAL-TREATMENT; AND/OR ADENOMYOMA; PELVIC PAIN; THERAPY; TRIAL; WOMEN;
D O I
10.1016/j.tjog.2017.12.036
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing the recurrence of postoperative adenomyosis-related symptoms. Materials and methods: From January 2005 through December 2014, a retrospective study including 133 patients with symptomatic adenomyosis undergoing conservative uterine-sparing surgery followed by gonadotropin-releasing hormone agonist treatment was conducted. We excluded the 18 patients who did not meet the inclusion criteria. The patients of intervention group (n = 54) received a levonorgestrelreleasing intrauterine system (LNG-IUS), which was inserted after surgery. The patients without LNG-IUS insertion were enrolled in the control group (n = 61). The primary outcome was improvement of adenomyosis-related dysmenorrhea, which was evaluated by the visual analog scale (VAS) and by hemoglobin (Hgb) and CA-125 levels. Results: Over a 12-month follow-up, the intervention group exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean +/- SD: 6.5 +/- 2.5 vs 4.1 +/- 3.6, p = 0.001) and a greater elevation in the Hgb level (2.1 +/- 1.9 vs 1.0 +/- 1.7, p = 0.008) than the control group. At the end of the 24-month follow-up period, the intervention group also exhibited a greater reduction in dysmenorrhea as assessed with a VAS score (mean +/- SD 6.1 +/- 2.7 vs 3.7 +/- 3.7, p = 0.002) and a greater elevation in the Hgb level (1.9 +/- 2.1 vs 0.7 +/- 1.8, p = 0.022) than the control group. The CA-125 level was significantly lower in the intervention group during the postoperative follow up (12th month follow-up, intervention vs control, 24.5 +/- 28.8 vs 50.1 +/- 44.0, p = 0.005; 24th month follow-up, 28.6 +/- 26.2 vs 75.4 +/- 68.5, p = 0.002). Conclusion: The maintenance therapy of LNG-IUS is effective and well accepted for long-term therapy after conservative surgery for patients with adenomyosis. (C) 2018 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 50 条
  • [41] Body composition in users of levonorgestrel-releasing intrauterine system
    Dal'Ava, N.
    Bahamondes, L.
    Bahamondes, M. V.
    de Oliveira Santos, A.
    Monteiro, I.
    [J]. 14TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI), 2011, : 207 - 211
  • [42] Use of the levonorgestrel-releasing intrauterine system and breast cancer
    Tjalma, WAA
    Trinh, XB
    van Dam, PA
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 107 (01): : 207 - 208
  • [43] Use of the levonorgestrel-releasing intrauterine system and breast cancer
    Backman, T
    Rauramo, I
    Jaakkola, K
    Inki, P
    Vaahtera, K
    Launonen, A
    Koskenvuo, M
    [J]. OBSTETRICS AND GYNECOLOGY, 2005, 106 (04): : 813 - 817
  • [44] Levonorgestrel-releasing intrauterine system for endometrial hyperplasia (Review)
    Mittermeier, T.
    Farrant, C.
    Wise, M. R.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (09):
  • [45] Levonorgestrel-releasing intrauterine system and the risk of breast cancer
    Zurcher, Aline
    Stute, Petra
    [J]. GYNAKOLOGISCHE ENDOKRINOLOGIE, 2022, 20 (04): : 285 - 287
  • [46] Levonorgestrel-releasing intrauterine system and breast cancer; Is there an association?
    Al Kiyumi, Maisa Hamed
    Al Battashi, Kauthar
    Al-Riyami, Hana Ali
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (09) : 1749 - 1749
  • [47] Subject and clinician experience with the levonorgestrel-releasing intrauterine system
    Jensen, Jeffrey T.
    Nelson, Anita L.
    Costales, Antonio C.
    [J]. CONTRACEPTION, 2008, 77 (01) : 22 - 29
  • [48] Levonorgestrel-Releasing Intrauterine System and Iron Overload Syndrome
    da Motta, Marcia Vieira
    da Motta, Eduardo Vieira
    [J]. CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2013, 6 : 93 - 97
  • [49] Hysteroscopic management of displaced levonorgestrel-releasing intrauterine system
    Kuzel, David
    Hrazdirova, Lucie
    Kubinova, Kristyna
    Dundr, Pavel
    Cibula, David
    Mara, Michal
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2013, 39 (05) : 1014 - 1018
  • [50] LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE
    LUUKKAINEN, T
    LAHTEENMAKI, P
    TOIVONEN, J
    [J]. ANNALS OF MEDICINE, 1990, 22 (02) : 85 - 90